Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Columvi (glofitamab-gxbm)
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Columvi (glofitamab-gxbm)
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase. On the other hand, Glofitamab (glofitamab-gxbm) is a bispecific CD20-directed cytolytic antibody indicated for the treatment of certain types of non-Hodgkin lymphoma. When deciding between the two, it is crucial to consider the specific type of blood cancer being treated, as Rylaze is tailored for ALL, while Glofitamab is used for lymphomas targeting the CD20 antigen on B cells.
Difference between Rylaze and Columvi
| Metric | Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) | Columvi (glofitamab-gxbm) |
|---|---|---|
| Generic name | Asparaginase erwinia chrysanthemi (recombinant)-rywn | Glofitamab-gxbm |
| Indications | Acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase | Treatment of relapsed or refractory B-cell non-Hodgkin lymphoma |
| Mechanism of action | Hydrolyzes asparagine to aspartic acid and ammonia, which depletes asparagine levels and inhibits protein synthesis in leukemic cells | Targets CD20 on B cells and CD3 on T cells to direct T cells to kill B cells |
| Brand names | Rylaze | Columvi |
| Administrative route | Intramuscular injection | Intravenous infusion |
| Side effects | Allergic reactions, pancreatitis, glucose intolerance, thrombosis, bleeding, liver dysfunction, etc. | Cytokine release syndrome, infections, fatigue, infusion-related reactions, etc. |
| Contraindications | History of serious hypersensitivity to asparaginase erwinia chrysanthemi | None specifically listed; use may be contraindicated in certain patients based on clinical judgment |
| Drug class | Antineoplastic agent, enzyme | Antineoplastic agent, bispecific monoclonal antibody |
| Manufacturer | Jazz Pharmaceuticals | Roche |
Efficacy
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Efficacy in Lymphoma
Rylaze, also known as asparaginase erwinia chrysanthemi (recombinant)-rywn, is a medication used as a component of a multi-agent chemotherapeutic regimen for patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. It is specifically indicated for patients who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze functions by depleting the amino acid asparagine, which is necessary for the growth of leukemic cells. While primarily used in ALL, its efficacy in treating lymphoblastic lymphoma, which is a rare type of non-Hodgkin lymphoma, is also recognized due to the similar pathophysiology of lymphoblastic cells in these diseases.
The efficacy of Rylaze in lymphoma patients is assessed based on its ability to sustain asparagine depletion. In clinical trials, Rylaze demonstrated a consistent pharmacodynamic profile, maintaining asparagine depletion levels that are associated with good clinical outcomes in patients with hypersensitivity to E. coli-derived asparaginase. The use of Rylaze in this context allows for the continuation of asparaginase therapy, which is a critical component of the treatment regimen for lymphoblastic lymphoma.
Columvi (glofitamab-gxbm) Efficacy in Lymphoma
Columvi, known by its generic name glofitamab-gxbm, is a bispecific CD20xCD3 T-cell engager used for the treatment of B-cell lymphomas. It is designed to redirect T cells to engage and eliminate B cells by binding to CD20 on B cells and CD3 on T cells. Glofitamab is being investigated in clinical trials for its efficacy in treating various types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
In early clinical trials, Columvi has shown promising efficacy in heavily pretreated patients with relapsed or refractory B-cell lymphomas, including those who have not responded to or have relapsed after CAR-T therapies or other treatments. The response rates observed in these studies suggest that glofitamab may offer a new therapeutic option for patients with difficult-to-treat B-cell lymphomas. However, it is important to note that further studies are necessary to confirm these findings and to determine the long-term efficacy and safety profile of Columvi in lymphoma patients.
Regulatory Agency Approvals
Rylaze
-
Food and Drug Administration (FDA), USA
Columvi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Rylaze or Columvi today
If Rylaze or Columvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us